#Pharmaceuticals

🏢Release 📈 Stocks

Ajinomoto Bio-Pharma Services Unveils Global Brand Refresh in Tokyo

October 5, 2026 (13 days ago)

Ajinomoto Bio-Pharma Services introduces a new global brand identity to emphasize its specialized contract development and manufacturing capabilities within the pharmaceutical sector.

2802.T

🌍 ASIA Read More →

🏢Release 📈 Stocks

Astellas Pharma Reports Positive Real-World Sleep Data for VEOZAH

October 2, 2026 (16 days ago)

Astellas Pharma's VEOZAH shows significant improvements in sleep quality and menopause symptoms in new real-world study data, bolstering the drug's commercial outlook.

ALPMY

🌍 GLOBAL Read More →

📰News 📈 Stocks

Eli Lilly's Orforglipron Hits Primary Endpoints in Phase 3 ACHIEVE-4 Trial

October 1, 2026 (18 days ago)

Eli Lilly's oral GLP-1 drug orforglipron demonstrates significant cardiovascular safety and efficacy in phase 3 trials, showing a 16% lower risk of…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Veeva Systems Expands Global Footprint as Servier Adopts OpenData Platform

September 30, 2026 (18 days ago)

Veeva Systems secures a major expansion as Servier adopts Veeva OpenData to standardize customer reference information across 80+ countries, bolstering Veeva's AI-ready…

VEEV

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Insilico Medicine Targets $36.5B GLP-1 Market With New GIPR Antagonist

September 30, 2026 (19 days ago)

Insilico Medicine advances its drug pipeline with the nomination of ISM1354, aiming to capture market share in the high-growth weight management sector…

Insilico Medicine LLY

🌍 AMERICAS Read More →

🏢Release 🌐 Macro — 📊 Neutral

PhRMA Appoints Former House Majority Leader to Lead Industry Advocacy

September 29, 2026 (19 days ago)

PhRMA taps veteran political and business leader to steer the pharmaceutical industry through a period of significant legislative and regulatory scrutiny in…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eli Lilly Orforglipron Outperforms Novo Nordisk Semaglutide in Clinical Data

September 29, 2026 (20 days ago)

Eli Lilly's orforglipron outperforms Novo Nordisk's oral semaglutide in recent clinical trials, showing superior weight loss and A1C reduction metrics that could…

LLY NVO

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Eli Lilly Targets Global Access to Diabetes and Obesity Drugs by 2040

September 28, 2026 (20 days ago)

Eli Lilly commits to a long-term global expansion plan, aiming to provide equitable access to its innovative diabetes and obesity portfolio in…

LLY

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

FDA Approves Eli Lilly's Olumiant for Pediatric Alopecia Areata Treatment

September 25, 2026 (23 days ago)

Eli Lilly secures FDA approval for Olumiant in pediatric alopecia areata, marking a key label expansion following successful Phase 3 clinical trial…

LLY

🌍 AMERICAS Read More →

📰News 📈 Stocks

Novo Nordisk Shares Plunge 7% as Patent Expiry and Competition Concerns Mount

September 23, 2026 (26 days ago)

Novo Nordisk shares fell 7% after the company confirmed semaglutide patent expirations starting in 2032 and reported underwhelming Phase 3 trial results…

NVO LLY

🌍 GLOBAL Read More →

📰News 📈 Stocks

NVIDIA and Eli Lilly Post Triple-Digit and 48% Revenue Growth Respectively

September 21, 2026 (27 days ago)

NVIDIA and Eli Lilly showcase distinct growth trajectories, with NVIDIA leading in AI infrastructure scaling and Eli Lilly dominating the GLP-1 market…

NVDA LLY

🌍 GLOBAL Read More →

📰News 📈 Stocks

Novo Nordisk Shares Slip 6% as Long-Term Growth Targets Meet Peer Averages

September 21, 2026 (27 days ago)

Novo Nordisk shares dropped 6% following a capital markets day where the firm set long-term growth targets in line with industry peers,…

NVO

🌍 EUROPE Read More →